Not a member? Sign Up

Reasons for Joining

    Address your challenges through knowledge sharing with peers from our global network of specialists.

    Benchmark your business initiatives with the who's who in the field.

    Hear from industry pioneers how to maximize ROI in today's challenging economy.

    And best of all It's FREE!
Sign in using your existing
Pharma IQ account
Username or Email:

Sign Up  |  Already a member? Sign In  |  Visit IQPC.com  
Pharma IQ

Pharma & Outsourcing Practice: Biosimilars - Guidelines, Players, Providers


Pharma & Outsourcing Practice: Biosimilars - Guidelines, Players, Providers

IN THIS ISSUE:

  • Outsourcing for biosimilars
  • Approvals and guidance
  • Biosimilar monoclonal antibodies
  • Players and their responsibility
  • Service Providers
  • GET THE COMPLETE REPORT 


In Europe, 20 biosimilars have been reviewed to date, resulting in 14 approved products, with four and two products, respectively, using the same filgrastim; and three and two products, respectively, using the same erythropoietin. Two biosimilar products submitted for authorization have been rejected and four have been withdrawn. And only very recently, a Marketing Authorization Application (MAA) for the first biosimilar monoclonal antibody was submitted to the European Medicines Agency (EMA, formerly EMEA).

In the US, no products have been approved yet under a biosimilar pathway, but two have been approved under the 505(b)(2) regulatory pathway of the Federal Food, Drug, and Cosmetics Act: 1. Enoxaparin as the generic of Lovenox, a low-molecular heparin; and 2. Omnitrope, a generic of the growth hormone Genotropin.

Since March 2010, the US provisions for biosimilars have been defined via the Patient Protection and Affordable Care Act (PPACA). They are set out in PPACA Sections 3139 and 7001 to 7003. The latter sections are the “Biologics Price Competition and Innovation Act of 2009” (BPCIA), which inserts Sections 351(k), 351(l), and 351(m) into the Public Health Service Act (PHSA), introducing the approval pathway for biosimilars.

https://www.pharmatching.com/inforena/pharma-outsourcing-practice-biosimilars-guidelines-players-providers

Have Your Say
Rate this feature and give us your feedback in the comments section below
Download
Rate this Whitepaper: (Be the First!)


Tags:   biosimilars | pharma outsourcing | biosimilars players | bisomilars guidelines | biosimilars market | biosimilar monoclonal antibodies | Outsourcing for biosimilars | biosimilars approvals


To receive the white paper on this topic please submit your information in the form below.

By entering in your information and submitting the form, you give the sponsor permission to contact you regarding their product.



Leave this field empty
Already an IQ member? Sign in
First Name:  *
Last Name:  *
Job Title:  *
Phone:  *
E-mail:  *
Company:  *
Country:  *
State  *
User Name:  *
Password:  *
Confirm Password:  *
Which of the following best describes your area of expertise?

   Yes, I'd like to also sign up for Pharma IQ.



By clicking "Submit" you are indicating that you have read, understood and agree to e-BIM's User Agreement and Privacy Policy.

Use of this site constitutes acceptance of IQPC's Privacy Policy.

A confirmation message will be sent to the e-mail above.
Please click on the link that has been sent to your e-mail to start using your account.
Advertisement

Advertisement